share_log

BMO Capital Maintains Outperform on Acrivon Therapeutics, Lowers Price Target to $24

BMO Capital Maintains Outperform on Acrivon Therapeutics, Lowers Price Target to $24

BMO Capital维持Acrivon Therapeutics的跑赢大盘,将目标股价下调至24美元
Benzinga ·  2023/11/10 15:01

BMO Capital analyst Etzer Darout maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Outperform and lowers the price target from $25 to $24.

BMO Capital分析师埃策·达鲁特维持Acrivon Therapeutics(纳斯达克股票代码:ACRV)跑赢大盘,并将目标股价从25美元下调至24美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发